Cargando…
Impact of COVID-19 on monitoring of therapeutic unfractionated heparin
Autores principales: | Adie, Sarah K., Farina, Nicholas |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Springer US
2020
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7437961/ https://www.ncbi.nlm.nih.gov/pubmed/32815032 http://dx.doi.org/10.1007/s11239-020-02250-0 |
Ejemplares similares
-
Establishing the heparin therapeutic range using aPTT and anti-Xa measurements for monitoring unfractionated heparin therapy
por: Byun, Jung-Hyun, et al.
Publicado: (2016) -
Monitoring of Unfractionated Heparin in Severe COVID-19: An Observational Study of Patients on CRRT and ECMO
por: Streng, Alexander S., et al.
Publicado: (2020) -
Management of therapeutic unfractionated heparin in COVID‐19 patients: A retrospective cohort study
por: Weeks, Lachelle D., et al.
Publicado: (2021) -
Unfractionated and low molecular weight heparin
por: Lima, Marcelo, et al.
Publicado: (2014) -
Validation of high concentrated thrombin time assay for unfractionated heparin monitoring
por: Apipongrat, Dollapak, et al.
Publicado: (2022)